Shuɗin methylene don rikicewar ƙwaƙwalwa daga ifosfamide: bitar shaidu

Ifosfamide magani ne mai haɗa rukunin alkyl wanda ake yawan amfani da shi wajen kula da kansa, ciki har da sarcoma, lymphoma, kansar bakin mahaifa, da kansar huhu. A wani ƙaramin ɓangare na marasa lafiya, yana haifar da wani abu mai tayar da hankali: sa'o'i zuwa kwanaki bayan fara shigar da maganin ta jijiya, mara lafiya yana shiga ruɗani, rashin natsuwa, da gyangyaɗi, wani lokaci ma yana nuna matsanancin rikicewar tunani ko ya kasa amsawa. Hotunan binciken jiki galibi ba sa nuna wani abin da ya saɓa wa al'ada. Sannan, a yawancin lokuta, alamomin sukan kau cikin 'yan kwanaki bayan an dakatar da maganin. Likitocin kansa suna kiran wannan rikicewar aikin ƙwaƙwalwa da ifosfamide ke haddasawa, kuma rashin iya hango aukuwarsa ne ya sa har yanzu ake tattauna rahoton shekarun 1990 na wani rini mai shuɗi da ya kawar da shi a sassan asibiti.

Tambayar da wannan maƙala ke amsawa tana da takamaiman iyaka. Shin shuɗin methylene yana magance wannan rikicewar ƙwaƙwalwa ko hana ta, kuma yaya ƙarfin shaidun yake? Amsa a taƙaice ita ce rahotannin ceton marasa lafiya suna burgewa, amma shaidun suna da rauni, kuma shaidun rigakafin sun ma fi rauni. Wannan bambanci yana da muhimmanci domin wannan shawara ce da ake yanke wa a asibiti cikin matsin lamba, ba shawarar amfani da ƙarin abinci a gida ba.

Yadda rikicewar ƙwaƙwalwar take bayyana

Alamomi yawanci suna farawa yayin shigar da ifosfamide ta jijiya ko jim kaɗan bayan haka: rashin sanin inda mutum yake ko lokacin da ake ciki, rashin natsuwa, ganin ko jin abubuwan da ba su wanzu, yawan gyangyaɗi, wani lokaci farfaɗiya ko suma mai zurfi. EEG sau da yawa yana nuna raguwar saurin aikin lantarki a faɗin ƙwaƙwalwa. Haɗarin yana ƙaruwa da yawan adadin magani, saurin shigar da shi ta jijiya, raunin aikin koda, ƙarancin albumin, cutar ƙwaƙwalwa da ta gabata, da shan magungunan da ke sa gyangyaɗi a lokaci guda. Yawancin lokutan suna warkewa da kulawar tallafi kaɗai cikin kwana ɗaya zuwa uku, ko da yake ana samun lokuta masu tsanani ko masu ɗaukar lokaci, kuma sake ba da ifosfamide na iya jawo sake aukuwar matsalar.

Wannan yadda matsalar ke tafiya da kanta shi ne abin da ya kamata ka fahimta kafin karanta kowane rahoto game da shuɗin methylene. Maganin da aka bayar a rana ta biyu ta ruɗani, sannan aka samu waraka a rana ta uku, ƙila bai yi komai ba. Dole ne a auna kowace da'awa da ke ƙasa da yiwuwar warkewa ba tare da maganin ba.

Inda ra'ayin amfani da shuɗin methylene ya samo asali

A 1994, wata ƙungiya a Bern ta ba da rahoton sakamakon binciken fitsari a marasa lafiyar da ke samun ifosfamide wanda ya yi kama da wata cuta mai wuya ta gado da ke shafar canja wurin electron a mitochondria, tare da yawan glutaric acid da sarcosine fiye da kima. Sun kuma bayyana kawar da rikicewar ƙwaƙwalwa cikin sauri bayan ba da shuɗin methylene a wani gajeren rahoto a Lancet. Bitar tsarin aikin da ta biyo baya ta gabatar da hanyoyi uku masu aiki tare, ba hanya ɗaya kaɗai ba.

Na farko, ifosfamide yana tarwatsewa a hanta ya samar da chloroethylamine mai yawa, wanda yake haɗuwa da cysteine ya samar da wani sinadari mai tsarin zobe da ke ɗauke da sulfur, mai suna thialysine ketimine. Wannan sinadari yana hana aikin flavoproteins a jerin matakan numfashin mitochondria, yana toshe oxidation na NADH na al'ada. Shuɗin methylene, a matsayin madadin mai karɓar electron, na iya maye gurbin matakin da aka toshe. Wannan dalili an samo shi ne daga tsohon amfani da shi wajen wasu nau'o'in glutaric aciduria.

Na biyu, toshewar jerin redox tare da taruwar aldehyde fiye da kima daga sarrafa ifosfamide a jiki suna rage rabon NAD zuwa NADH, wanda yake raunana kawar da aldehyde da samar da glucose. Shuɗin methylene yana sake yin oxidation na NADH zuwa NAD, yana dawo da wani ɓangare na wannan daidaito. Wannan halin jigilar electron a redox shi ne tushen yawancin sauran tasirin da aka gabatar cewa yana yi a ƙwayoyin halitta, kuma yana da amfani a fahimci ƙa'idar yadda shuɗin methylene ke jigilar electrons dabam da wannan takamaiman amfani na asibiti.

Na uku, shuɗin methylene yana hana aikin enzymes na amine oxidase waɗanda da ba haka ba za su canja chloroethylamine zuwa chloroacetaldehyde, wani samfurin sarrafa magani da ke da guba kai tsaye ga jijiyoyi da koda, wanda ake samu a jinin marasa lafiyar ifosfamide ba tare da yana ɗaure da wani abu ba. Ƙarancin chloroacetaldehyde yana nufin ƙarancin lalacewar da ke biyo baya, ciki har da ƙarancin tangarda ga oxidation na fatty acid da aka nuna a mitochondria da aka ware.

Tsarin aikin yana da ma'ana kuma yana da cikakken bayani fiye da yadda aka saba. Kasancewar abu mai yiwuwa ba hujjar tabbatar da shi ba ce, amma yana bayyana dalilin da ya sa likitocin kansa suka ɗauki rahotannin farko da muhimmanci.

Rahotannin ceto: da sauri, amma ba tare da rukunin kwatantawa ba

Rahoton da aka fi ambata har yanzu shi ne na 1995 game da wata mace mai shekaru 68 da ke da kansar bakin mahaifa, wadda ta shiga ruɗani da rashin natsuwa bayan samun ifosfamide 5 g a kowace murabba'in mita cikin sa'o'i 24. CT ɗinta bai nuna matsala ba, kuma EEG ɗinta ya nuna raguwar saurin aikin lantarki a faɗin ƙwaƙwalwa. An ba ta shuɗin methylene 50 mg ta jijiya cikin mintuna biyar, kuma an bayyana cewa ta farka tana magana mai ma'ana cikin mintuna goma. Mintuna goma sun fi lokacin da matsalar ke ɗauka wajen warkewa da kanta gajarta sosai, shi ya sa wannan rahoto guda ya sami irin wannan muhimmanci.

Jerin rahotannin da suka biyo baya ba su da ban mamaki haka. A wani binciken baya-baya na marasa lafiyar ifosfamide 52, 12 sun sami rikicewar ƙwaƙwalwa ta mataki na 2 ko fiye; takwas daga cikinsu sun sami shuɗin methylene 50 mg ta jijiya sau shida a rana. Huɗu sun warke gaba ɗaya cikin sa'o'i 24, ciki har da wani mai tsananin matsala da ya warke cikin kusan awa ɗaya; wasu biyu sun warke zuwa sa'o'i 48, sauran biyu kuma zuwa sa'o'i 72. Amma dukan marasa lafiya huɗun da ba su sami maganin ba su ma sun warke cikin sa'o'i 48, kamar yadda marubutan da kansu suka ruwaito. Wani jerin rahotannin yara 15 ya sami amfanin da za a iya nunawa a yaro ɗaya kawai cikin biyar da aka ba maganin. Rahotannin manya biyu da aka wallafa a 2018, waɗanda aka ba 50 mg duk bayan sa'o'i huɗu, sun fara samun sauƙi ne kawai bayan sa'o'i 12 zuwa 16, suka kuma koma yadda suke kafin matsalar bayan kwana biyu zuwa uku; wannan bai bambanta da lokacin warkewa ta kulawar tallafi ba.

Wata bitar wallafe-wallafe ta 2020 ta ƙidaya marasa lafiya 38 da aka wallafa rahotanninsu waɗanda aka ba shuɗin methylene, kuma an bayyana kusan kashi uku cikin huɗu na su a matsayin waɗanda suka sami sauƙi mai kyau. Wannan adadi yana sa a kwantar da hankali har sai an tuna cewa ana rubuta rahotannin masu warkewa da sauri, amma sau da yawa ba a rubuta na masu warkewa a hankali. Son wallafa sakamako mai jan hankali yana sa tarin rahotannin marasa lafiya su yi kama da sun fi ainihin abin da ke faruwa kyau.

Teburin shaidu: a rarrabe tsarin bincike

Teburin da ke ƙasa shi ne ginshiƙin wannan bita. Rahoton mutum ɗaya zai iya nuna yiwuwar abu kawai; jerin rahotanni ba tare da rukunin kwatantawa ba za su iya bayyana abin da ya faru kawai; kuma babu gwaje-gwajen ingancin magani na rabon bazuwar don wannan tambaya.

Matakin shaidu	Bincike	Tsarin bincike da marasa lafiya	Tsarin ba da shuɗin methylene	Abin da ya faru
Rahoton mara lafiya	Kupfer et al., Lancet 1994	Rahoton farko na jiyya tare da rahoton rigakafi guda; sakamakon binciken sinadaran jiki mai kama da glutaric aciduria	Jiyya 50 mg IV; rigakafi ta baki	An ruwaito kawar da matsalar cikin sauri; mara lafiya na biyu bai sake samun matsalar ba bayan sake ba shi ifosfamide
Rahoton mara lafiya	Zulian et al., N Engl J Med 1995	Mace mai shekaru 68, kansar bakin mahaifa, ruɗani bayan ifosfamide 5 g/m2 cikin 24 h	50 mg IV cikin 5 min, ruwan magani na 1 percent	Ta farka tana magana mai ma'ana cikin 10 min
Jerin rahotanni, binciken baya-baya tare da kwatanta marasa lafiya da ba a ba maganin ba	Pelgrims et al., Br J Cancer 2000	Marasa lafiyar ifosfamide 52; 12 masu rikicewar ƙwaƙwalwa ta mataki na 2 ko fiye; an ba 8 magani, ba a ba 4 ba	Jiyya 50 mg IV sau shida a rana; rigakafi 50 mg sau huɗu a rana ga marasa lafiya 3	Waɗanda aka ba magani: 4 cikin 8 sun warke cikin 24 h, duka cikin 72 h. Waɗanda ba a ba magani ba: dukan 4 sun warke cikin 48 h
Jerin rahotanni	Turner et al., Clin Oncol 2003	Marasa lafiya 4 masu matsalar da ta taso kwatsam, daga baya an ba 2 rigakafi	Sau da yawa 50 mg ta baki sau uku a rana	An ruwaito babban sauƙi cikin 24 h; matsalar ta fi sauƙi bayan sake ba da ifosfamide tare da rigakafi
Jerin rahotanni, na yara	Dufour et al., Arch Pediatr 2006	Rahotannin yara 15 masu rikicewar ƙwaƙwalwa	Jiyya 50 mg IV duk bayan 4 h; rigakafi duk bayan 6 h	An ga amfani a 1 cikin 5 da aka ba magani; babu sake aukuwar matsalar a 2 cikin 2 da aka ba rigakafi
Binciken motsin magani a jiki, ba tare da rukunin kwatanta inganci ba	Aeschlimann et al., Drug Metab Dispos 1998	Marasa lafiyar kansar huhu 9 da ke samun ifosfamide, mesna, etoposide	50 mg ta baki sau uku a rana daga yammacin ranar da ke gab da maganin kansa	An iya jure maganin; babu muhimmin sauyi wajen kunna ifosfamide; an yi da'awar kariya ga jijiyoyi amma babu rukunin kwatantawa
Binciken baya-baya, mai mai da hankali kan rigakafi	Sweiss et al., Drug Safety 2008	Marasa lafiya 19 da ke samun ifosfamide mai yawa; 8 masu rikicewar ƙwaƙwalwa; an sake ba 5 ifosfamide tare da rigakafi	Shuɗin methylene don rigakafi, tsarin ba da shi ya bambanta	Dukan 5 da aka sake ba ifosfamide tare da rigakafi sun sake samun rikicewar ƙwaƙwalwa
Kwatanta zagayen jiyya a binciken baya-baya	Richards et al., J Oncol Pharm Pract 2011	Zagayen jiyya 166 tare da shuɗin methylene, thiamine, ko albumin don rigakafi idan aka kwatanta da babu rigakafi	Tsarin rigakafi daban-daban	Rikicewar ƙwaƙwalwa a 21.1 percent na zagayen da aka yi rigakafi idan aka kwatanta da 8.4 percent ba tare da rigakafi ba; akwai yiwuwar dalilin zaɓar rigakafi ya rikita kwatancen
Jerin rahotannin baya-baya	Jerin rahotannin yara da matasa na MD Anderson, 2025	Marasa lafiya 24 masu rikicewar ƙwaƙwalwa; 20 sun sami shuɗin methylene	Mafi yawanci 50 mg IV duk bayan 6 h, adadin ba da magani na tsakiya 5	19 cikin 20 sun warke cikin 24 zuwa 120 h ba tare da kwatanta da waɗanda ba a ba magani ba; matsalar ta sake faruwa a 3 cikin 5 da aka sake ba ifosfamide tare da rigakafi

Idan aka bi ginshiƙin sakamako daga sama zuwa ƙasa, tsarin yana daidaita: labaran farko masu ban mamaki, sannan sakamako masu ƙara jinkiri da gaurayuwa yayin da adadin marasa lafiya ya ƙaru kuma aka fara samun kwatance. Wannan alama ce ta wani matakin jiyya wanda tasirinsa na gaske, idan yana da shi, bai da yawa.

Shaidun rigakafi ba su da ƙarfi

Da'awar rigakafi tana buƙatar nata hukuncin domin tana tasiri ga rubuta magani a zahiri. Bayan ƙwarewar farko ta Bern da ifosfamide ta baki tare da 50 mg sau uku a rana, inda ba a lura da guba ga jijiyoyi ba, cibiyoyi da dama sun gwada shuɗin methylene don rigakafi yayin sake ba da ifosfamide. Sakamakon ya bambanta. Wasu marasa lafiya da aka sake ba ifosfamide sun sami matsalar da ta fi sauƙi ko ba su sami ta ba; a wasu jerin rahotannin kuma, kowane mara lafiya da aka sake ba ifosfamide tare da rigakafi ya sami rikicewar ƙwaƙwalwa duk da haka. Wani kwatancen baya-baya ya sami rikicewar ƙwaƙwalwa fiye da yawa a zagayen jiyya da aka yi rigakafi fiye da waɗanda ba a yi ba, kusan tabbas domin an zaɓi marasa lafiyar da ke da haɗari mafi girma don rigakafin.

Masu rubuta jagororin asibiti sun lura da hakan. Jagorar haɗin gwiwa kan guba ga jijiyoyi daga ƙungiyoyin Turai na likitocin kansa da likitocin jijiyoyi ta kammala cewa babu gwaje-gwajen da ke da rukunin kwatantawa, kuma ba za a iya ba da shawarar shuɗin methylene don rigakafi ko jiyya bisa shaidun da ake da su yanzu ba. Bayanan rubuta magani da wasu ƙa'idojin asibitoci sun ɗauki matsayi mai sassauci, suna cewa ana iya la'akari da shi don rikicewar ƙwaƙwalwa mai matsakaicin tsanani ko mai tsanani. Duka matsayi biyun suna bayyana bayanai iri ɗaya; bambancinsu kawai shi ne irin muhimmancin da za a ba rahotannin mutum ɗaya idan babu wani zaɓi mafi kyau.

Mahallin ƙwararru da wanda ba likitan kansa ba ya kamata ya sani

Abubuwa uku na aiki suna tsara kowace shawara a gefen gadon mara lafiya. Na farko, wannan amfani da shuɗin methylene ba ya cikin amfanin da aka amince da shi a hukumance; ana ba da shi ta jijiya a asibiti, yawanci 50 mg duk bayan sa'o'i huɗu zuwa takwas har sai alamomin sun kau. Ba maganin gida ba ne, kuma wannan maƙala ba jagorar adadin magani ba ce.

Na biyu, shuɗin methylene mai hana aikin monoamine oxidase A ne, kuma yana da gargaɗi mai ƙarfi a cikin akwatin bayani game da ciwon taruwar serotonin idan aka haɗa shi da magungunan baƙin ciki masu tasiri ga serotonin da wasu opioids. An kuma ba da rahoton wannan ciwon musamman yayin jiyyar rikicewar ƙwaƙwalwa daga ifosfamide. Haka kuma, an haramta amfani da shi ga masu ƙarancin glucose-6-phosphate dehydrogenase saboda haɗarin lalacewar ƙwayoyin jini ja. Dole ne a yi la'akari da bayanan aminci da hulɗar magunguna da babbar tambayar ko amfani da shuɗin methylene yana da aminci ga wani takamaiman mara lafiya kafin a buɗe kowace kwalbar shuɗin maganin.

Na uku, dakatar da ifosfamide, samar da isasshen ruwa, daidaita electrolytes da sauran magungunan da ake sha tare, da tabbatar da cewa babu wasu abubuwan da ke jawo ruɗanin, su ne ginshiƙin kulawa. Inda ake amfani da shuɗin methylene, ana ƙara shi ne a kan wannan ginshiƙi, ba a maye gurbinsa da shi ba. Koyon yadda ake karanta binciken shuɗin methylene yana taimakawa a nan: a tambayi ko rahoton yana da rukunin kwatantawa, yadda aka tantance tsananin rikicewar ƙwaƙwalwa, wasu abubuwan da suka sauya a lokaci guda, da ko lokacin warkewa ya bambanta da sanannen lokacin kwana ɗaya zuwa uku da matsalar ke ɗauka wajen warkewa da kanta.

A taƙaice

Amfani da shuɗin methylene don rikicewar ƙwaƙwalwa daga ifosfamide ya dogara da tsarin aikin mitochondria mai ma'ana, kaɗan daga rahotannin ceto masu sauri da gaske masu burgewa, da jerin rahotanni masu yawa waɗanda marasa lafiyar da aka ba magani da waɗanda ba a ba su ba suke warkewa cikin kusan lokaci iri ɗaya. A matsayin jiyyar ceto ga rikicewar ƙwaƙwalwa mai tsanani ko mai ɗaukar lokaci, wasu likitocin kansa suna ganin amfani da shi yana da ma'ana saboda rashin wasu zaɓuɓɓuka. Amma shaidun ba su goyi bayan amfani da shi a matsayin rigakafi na yau da kullum ba. Duk wanda ya fuskanci wannan tambaya, ko mara lafiya ne, mai kula da shi, ko ma'aikacin lafiya, ya kamata ya ɗauke ta a matsayin hukuncin ƙwararru ga mara lafiyar da aka kwantar a asibiti, bisa yanayin kowane mutum, kuma ya karanta rahotannin warkewa cikin sauri a matsayin zato da ke buƙatar gwaji, ba hujja ba.